노른자모양황반변성 환자에서 유리체강내 베바시주맙 주입술을 시행한 환자 1예
A Case of Adult‐Onset Vitelliform Dystrophy Treated with Intravitreal Injection of Bevacizumab
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
목적: 성인에서 발병한 노른자모양황반변성(Adult-onset vitelliform macular dystrophy, AOVD)을 진단받은 환자에게 유리체강 내 베바시주맙 주입술을 시행을 한 1예를 보고하고자 한다. 증례요약: 47세 여성 환자가 양안 시야 흐림 및 변시증을 주소로 외래로 내원하였다. 안저 검사에서 양안에서 작고 둥근 노란색 반점이망막중심속오목 근처에서 보이며 황반부 하액이 축적된 양상을 보였다. 광간섭단층촬영에서 망막색소상피를 따라 두꺼운 과반향 병변(hyperreflective lesion)이 보이며 이와 함께 신경 망막박리가 동반되었다. 양안에 각각 3차례 유리체강 내 베바시주맙 주입술을시행 후 광간섭단층촬영 및 안저 검사에서 병변의 호전을 보이지 않았다.
Abstract
Purpose: To report a patient diagnosed with adult-onset vitelliform dystrophy (AOVD) who received an intravitreal injection ofbevacizumab in both eyes. Case summary: A 47-year-old female presented with blurred vision and metamorphopsia in both eyes. On color fundus photograph,small, round, yellowish dots on the foveola and subreitnal fluid were observed. Optical coherence tomography (OCT)showed thick hyperreflective structures in the retinal pigment epithelium (RPE) layer with serous retinal detachment and subretinalfluid. Despite an intravitreal injection of bevacizumab on both eyes, anatomical improvement was not observed on fundusphotography and OCT.
참고문헌 (18)
- Do P, "Adult-onset foveomacular vitelliform dystrophy", Optometry, 77, pp.156~166 (2006)
- Funk M, "Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab", Invest Ophthalmol Vis Sci, 50, pp.1025~1032 (2009)
- Wu L, "Twelvemonth safety of intravitreal injections of bevacizumab (Avastin):results of the Pan-American Collaborative Retina Study Group (PACORES)", Graefes Arch Clin Exp Ophthalmol, 246, pp.81~87 (2008)
- Kreutzer TC, "Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion", Br J Ophthalmol, 92, pp.351~355 (2008)
- Rabena MD, "Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion", Retina, 27, pp.419~425 (2007)
- Matsumoto Y, "Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease", Retina, 27, pp.426~431 (2007)
- Lee JY, "Spectral domain optical coherence tomography in a patient with adult-onset vitelliform dystrophy treated with intravitreal bevacizumab", Ophthalmic Surg Lasers Imaging, 40, pp.319~321 (2009)
- Petrukhin K, "Identification of the gene responsible for Best macular dystrophy", Nat Genet, 19, pp.241~247 (1998)
- Marmorstein AD, "Bestrophin, the product of the Best vitelliform macular dystrophy gene (VMD2), localizes to the basolateral plasma membrane of the retinal pigment epithelium", Proc Natl Acad Sci U S A, 97, pp.12758~12763 (2000)
- Sun H, "The vitelliform macular dystrophy protein defines a new family of chloride channels", Proc Natl Acad Sci U S A, 99, pp.4008~4013 (2002)
- Boon CJ, "The spectrum of ocular phenotypes caused by mutation in the BEST1 gene", Prog Retin Eye Res, 28, pp.187~205 (2009)
- Booij JC, "Course of visual decline in relation to the BEST1 genotype in vitelliform macular dystrophy", Ophthalmology, 117, pp.1415~1422 (2010)
- Jarc-Vidmar M, "Fundus autofluorescence imaging in Best’s vitelliform dystrophy", Klin Monatsbl Augenheilkd, 220, pp.861~867 (2003)
- Gass JDM, "Stereoscopic atlas of macular diseases: diagnosis and treatment", pp.304~311 (1997), Mosby
- Deutman AF, "Retina Vol. 2", pp.1210~1257 (2001), Mosby
- Spaide RF, "Vitelliform macular dystrophy", Ophthalmology, 113, pp.1392~1400 (2006)
- Montero JA, "Intravitreal bevacizumab for adult-onset vitelliform dystrophy: a case report", Eur J Ophthalmol, 17, pp.983~986 (2007)
- Abengoechea-Hernandez S, "Photodynamic therapy in adult-onset foveomacular vitelliform dystrophy", Arch Soc Esp Oftalmol, 82, pp.117~120 (2007)